Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design

BACKGROUND: The lack of adequate randomized clinical trials (RCT) has hindered identification of new therapies that are safe and effective for patients with primary focal segmental glomerulosclerosis (FSGS), especially in patients who fail to respond to corticosteroids and immunosuppressive therapie...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Trachtman, Howard, Vento, Suzanne, Gipson, Debbie, Wickman, Larysa, Gassman, Jennifer, Joy, Melanie, Savin, Virginia, Somers, Michael, Pinsk, Maury, Greene, Tom
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2011
Teme:
Study Protocol
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3045306/
https://ncbi.nlm.nih.gov/pubmed/21310077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2369-12-8
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items